These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22966847)

  • 21. Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia.
    Thomas D
    Lancet Oncol; 2012 Sep; 13(9):860-2. PubMed ID: 22935232
    [No Abstract]   [Full Text] [Related]  

  • 22. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.
    Puzzolo MC; Radice G; Peragine N; de Propris MS; Mariglia P; Vignetti M; Vitale A; Bassan R; Annunziata M; Gaidano G; Rambaldi A; Chiaretti S; Guarini A; Foà R
    Blood; 2021 Dec; 138(22):2290-2293. PubMed ID: 34297829
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
    Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
    Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol.
    Thyagu S; Minden MD; Gupta V; Yee KW; Schimmer AD; Schuh AC; Lipton JH; Messner HA; Xu W; Brandwein JM
    Br J Haematol; 2012 Aug; 158(4):506-14. PubMed ID: 22650180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Fielding AK
    Hematology Am Soc Hematol Educ Program; 2011; 2011():231-7. PubMed ID: 22160039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia.
    Gazeau N; Derrieux C; Nibourel O; Berthon C; Grardel N; Goursaud L; Boyer T; Dumezy F; Coiteux V; Quesnel B; Preudhomme C; Roche-Lestienne C; Duployez N
    Leukemia; 2020 Aug; 34(8):2230-2233. PubMed ID: 31988437
    [No Abstract]   [Full Text] [Related]  

  • 28. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report.
    Martinelli G; Iacobucci I; Storlazzi CT; Vignetti M; Paoloni F; Cilloni D; Soverini S; Vitale A; Chiaretti S; Cimino G; Papayannidis C; Paolini S; Elia L; Fazi P; Meloni G; Amadori S; Saglio G; Pane F; Baccarani M; Foà R
    J Clin Oncol; 2009 Nov; 27(31):5202-7. PubMed ID: 19770381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Hatta Y; Hayakawa F; Yamazaki E
    Int J Hematol; 2020 Oct; 112(4):439-458. PubMed ID: 32812190
    [No Abstract]   [Full Text] [Related]  

  • 31. [Acute lymphoblastic leukemia].
    Vilmer E; Dhedin N
    Rev Prat; 2002 Jan; 52(2):213-7. PubMed ID: 11915569
    [No Abstract]   [Full Text] [Related]  

  • 32. [Sustained molecular remission with a tyrosine kinase inhibitor alone for seven months in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Takahashi T; Shigeoka T; Suzukawa M; Ishido A; Tominaga T
    Rinsho Ketsueki; 2013 Feb; 54(2):210-3. PubMed ID: 23470829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia.
    Weston BW; Hayden MA; Roberts KG; Bowyer S; Hsu J; Fedoriw G; Rao KW; Mullighan CG
    J Clin Oncol; 2013 Sep; 31(25):e413-6. PubMed ID: 23835704
    [No Abstract]   [Full Text] [Related]  

  • 34. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Philadelphia Chromosome in an Infant With Pro-B Acute Lymphoblastic Leukemia.
    Das A; Bansal D; Sreedharanunni S; Naseem S
    J Pediatr Hematol Oncol; 2017 Jan; 39(1):79-80. PubMed ID: 27820127
    [No Abstract]   [Full Text] [Related]  

  • 36. The presence of Philadelphia chromosome does not confer poor prognosis in adult pre-B acute lymphoblastic leukaemia in the tyrosine kinase inhibitor era - a surveillance, epidemiology, and end results database analysis.
    Igwe IJ; Yang D; Merchant A; Merin N; Yaghmour G; Kelly K; Ramsingh G
    Br J Haematol; 2017 Nov; 179(4):618-626. PubMed ID: 29047122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lestingi TM; Hooberman AL
    Hematol Oncol Clin North Am; 1993 Feb; 7(1):161-75. PubMed ID: 8449857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients.
    Piccaluga PP; Martinelli G; Isidori A; Malagola M; Rondoni M; Paolini S; Amabile M; Iacobucci I; Baccarani M; Visani G
    Leukemia; 2008 Aug; 22(8):1617-8. PubMed ID: 18273047
    [No Abstract]   [Full Text] [Related]  

  • 39. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome--positive acute lymphoblastic leukemia.
    Ottmann OG; Larson RA; Kantarjian HM; le Coutre PD; Baccarani M; Hochhaus A; Kim DW; Fan X; Novick S; Giles FJ
    Leukemia; 2013 Jun; 27(6):1411-3. PubMed ID: 23138184
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.